---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-022153"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:34:56.151670+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma: Phase 1 CDI-988 well tolerated; Phase 1b planned for norovirus

## Summary
- All CDI-988 doses (100-1200 mg) well tolerated in Phase 1 SAD and MAD cohorts; no severe AEs.
- Treatment-emergent AEs in SAD: 28% (10/36) CDI-988 vs 40% (4/10) placebo; MAD: 53% (19/36) vs 92% (11/12).
- Company expects to initiate Phase 1b challenge study in norovirus-infected healthy subjects later in 2025.
- Headache most common AE; no clinically relevant ECG changes or pathology results reported.
- CDI-988 targets 3CL viral proteases; potential prophylaxis/treatment for norovirus and coronaviruses.

## SEC filing metadata
- accession: 0001641172-25-022153
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000164117225022153/0001641172-25-022153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000164117225022153/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-022153
- JSON: https://secwatch.observer/filing/0001641172-25-022153.json
- Plain text: https://secwatch.observer/filing/0001641172-25-022153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.